Johnson & Johnson Other Immunology — Sales to customers (Note 9) increased by 50.0% to $24.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 1100.0%, from $2.00M to $24.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful market penetration or growth of secondary immunology therapies, while a decrease may signal competitive pressure or product lifecycle maturity within this specific portfolio.
This metric represents the net revenue generated from the sale of pharmaceutical products within the 'Other Immunology'...
Comparable to secondary immunology or specialty pharmaceutical revenue segments reported by large-cap biopharmaceutical peers, often used to track the contribution of non-blockbuster assets.
jnj_segment_other_immunology_sales_to_customers_note_9| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.00M | $13.00M | $6.00M | $20.00M | $12.00M | $6.00M | $10.00M | $6.00M | $4.00M | $0.00 | $4.00M | $2.00M | $0.00 | $2.00M | $16.00M | $24.00M |
| QoQ Change | — | -23.5% | -53.8% | +233.3% | -40.0% | -50.0% | +66.7% | -40.0% | -33.3% | -100.0% | — | -50.0% | -100.0% | — | +700.0% | +50.0% |
| YoY Change | — | — | — | — | -29.4% | -53.8% | +66.7% | -50.0% | -33.3% | — | -33.3% | -50.0% | — | — | +300.0% | >999% |
We use cookies for analytics. See our Privacy and Cookie Policy.